share_log

Humacyte To Present Phase 3 Results Comparing Efficacy And Safety Of Tissue-Engineered Vessel To AV Fistulas In End-Stage Renal Disease Patients At VEITH Symposium On November 23, 2024

Humacyte To Present Phase 3 Results Comparing Efficacy And Safety Of Tissue-Engineered Vessel To AV Fistulas In End-Stage Renal Disease Patients At VEITH Symposium On November 23, 2024

Humacyte將在2024年11月23日的VEITH研討會上展示對比組織工程血管與動靜脈瘻在終末期腎病患者中療效和安全性的第三階段結果。
Benzinga ·  2024/11/22 06:02

Humacyte To Present Phase 3 Results Comparing Efficacy And Safety Of Tissue-Engineered Vessel To AV Fistulas In End-Stage Renal Disease Patients At VEITH Symposium On November 23, 2024

Humacyte將在2024年11月23日的VEITH研討會上展示比較組織工程血管與末期腎病患者動靜脈瘻的療效和安全性的三期結果。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論